Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

September 30, 2019

Focal Therapy, AuroLase, Shows Good Safety and Potential Effectiveness in Pilot Clinical Trial

News

Nanospectra Biosciences‘ AuroLase Therapy, a focal therapy for prostate cancer that uses gold-silica nanoparticles, showed a good safety profile and evidence of successfully eliminating the cancer in a pilot clinical trial. ... Read more

September 18, 2019

Study Describes New Imaging Technique for Detecting Prostate Cancer

News

A new imaging technique that combines ultrasound and photoacoustic imaging of the prostate delivers detailed information about the prostate’s anatomy and cancer location, identifying some cancers that would be invisible ... Read more

August 5, 2019

Xtandi Delays Disease Worsening in Metastatic Hormone-sensitive Prostate Cancer, Study Says

News

Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how spread the disease is, a Phase 3 ... Read more

July 18, 2019

Liquid Biopsy Could Help Identify Aggressive Prostate Cancers, Study Says

News

A non-invasive test that examines microRNAs — small RNA molecules — in urine may be used to identify aggressive prostate cancers with great accuracy, potentially avoiding unnecessary treatments for slow-growing ... Read more

June 26, 2019

Report Identifies Proteins That Drive Spread in Castration-resistant PC

News

Inhibiting the protein BRD4 can stop the migration of castration-resistant prostate cancer cells, regardless of the mechanism causing resistance to treatment, new research has shown. This suggests that BRD4 might ... Read more

June 5, 2019

Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives

News

Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate cancer, ... Read more

March 4, 2019March 4, 2019

Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds

News

African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans diagnosed ... Read more

January 24, 2019

Researchers Develop Computer Model to Predict Prostate Cancer Progression

News

A new study has yielded a new computer model to understand the progression of prostate cancer, which may yield insights into understanding the disease and providing care for patients. The ... Read more

January 14, 2019

Prostate Cancer Scoring Method May Not Accurately Predict Outcomes in Black Men, Study Suggests

News

Black men diagnosed with low-risk prostate cancer are two times more likely to actually have a more aggressive, fatal form of the disease than those of other races, suggesting that ... Read more